Updated:
New York Genome Center
The New York Genome Center is a nonprofit academic research institution founded in 2010 in New York, New York. It specializes in genomic research on...
New York Genome Center
The New York Genome Center is a nonprofit academic research institution founded in 2010 in New York, New York. It specializes in genomic research on neurodegenerative diseases, neuropsychiatric disorders, and cancer. The center offers services including whole genome sequencing and genomic analysis, as well as clinical diagnostic laboratory testing using next-generation sequencing technology.
General information
Firm type
other
Year founded
2010
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Tom Maniatis
Founding Board Chair
David Goldstein
Director
Sector focus
Frequently asked questions
What is the New York Genome Center's primary mission?
The New York Genome Center is a nonprofit consortium focused on accelerating genomic medicine through shared infrastructure and collaborative research. Its mission is to apply genomic science to improve human health, with a particular emphasis on cancer, rare diseases, and population health (per the center's public mission statement).
How does the New York Genome Center generate revenue?
The center generates revenue through fee-for-service sequencing and analysis for academic, pharmaceutical, and clinical clients. It also receives philanthropic donations, grant funding from sources like the NIH, and membership dues from its academic medical center members.
Does the New York Genome Center conduct its own research, or is it exclusively a service provider?
The center both operates a service-oriented sequencing facility and conducts its own independent research. Its scientific teams pursue projects in computational genomics, cancer biology, and neurogenomics, often in collaboration with member institutions (per publications and center webpages).
Which diseases or conditions does the New York Genome Center focus on?
The center's research and clinical work concentrates heavily on cancer genomics, rare genetic disorders, and neurodegenerative diseases. It also participates in large-scale population studies and infectious disease surveillance, as seen with its COVID-19 genomic monitoring for New York City (per public health partnerships).
How does the New York Genome Center relate to pharmaceutical companies?
The center works with pharmaceutical partners on clinical trials and biomarker discovery, providing sequencing and analysis services. It does not typically develop therapies itself but supports drug development through genomic data generation and interpretation (per the center's partnership descriptions).
Is the New York Genome Center affiliated with any specific university?
No, it is an independent nonprofit consortium jointly governed by 11 founding academic medical centers, including Columbia University, Weill Cornell Medicine, Rockefeller University, and Cold Spring Harbor Laboratory. It does not belong to a single institution (per the center's governance structure).
What is the relationship between the New York Genome Center and the New York Genome Center Foundation?
The New York Genome Center Foundation is a separate nonprofit charitable entity that supports community engagement, education, and philanthropic fundraising for the Center's programs. It is legally distinct from the research and clinical operations (per IRS filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: